Figure 4.
Pharmacogenomic Modeling of Drug Sensitivity
(A) Pan-cancer and cancer-specific ANOVA analyses for statistically significant interactions between differential drug sensitivity and CFEs. Cancer-specific interactions are divided into those identified in a single or multiple cancer-specific analyses.
(B) A summary of established pharmacogenomic interactions detected in this analysis including a subset of clinically approved markers. The total number of significant and significant large-effect interactions for each cancer type is provided. Testable interactions that were validated on the CTRP datasets are also indicated.
(C) Volcano plot with effect size (x axis) and significance (y axis) of large-effect cancer-specific pharmacogenomic interactions. Each circle corresponds to a significant CFE-drug interaction. Circle size is proportional to the number of altered cell lines, and the color indicates cancer type. A subset of interactions is labeled with drug name, target (italics), and name of the associated CFE (bold).
(D) Examples of cancer-specific pharmacogenomic interactions identified by our systematic ANOVA. Each circle represents the IC50 of an individual cell line. The co-incident resistance-associated EGFR T790M mutation is labeled.